Domitrovic T Nicholas, Hujer Andrea M, Perez Federico, Marshall Steven H, Hujer Kristine M, Woc-Colburn Laila E, Parta Mark, Bonomo Robert A
Louis Stokes Cleveland Department of Veterans Affairs Medical Center.
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Open Forum Infect Dis. 2016 Oct 21;3(4):ofw188. doi: 10.1093/ofid/ofw188. eCollection 2016 Oct.
Successful treatment of infections caused by multidrug-resistant (MDR) is thwarted by the emergence of antibiotic resistance and biofilm formation on prosthetic devices. Our aims were to decipher the molecular basis of resistance in a unique case of prosthetic valve endocarditis (PVE) caused by MDR . Five sequential MDR blood isolates collected during a 7-month period were recovered from a patient suffering from PVE previously exposed to β-lactam antibiotics. Minimum inhibitory concentrations (MICs) of several classes of antibiotics were used to indicate clinical resistance characteristics; relatedness of the isolates was determined using multilocus sequence typing and repetitive sequence-based polymerase chain reaction. Amplification and sequencing of regulatory and resistance genes was performed. All isolates belonged to ST 298, possessed , and were resistant to fluoroquinolones and carbapenems. In the course of therapy, we observed a >2-fold increase in cephalosporin resistance (4 µg/mL to >16 µg/mL). Sequencing of the AmpC regulator, R, revealed a D135N point mutation in cephalosporin-resistant isolates. Common carbapenemase genes were not identified. All isolates demonstrated a premature stop codon at amino acid 79 of the outer membrane protein OprD and mutations in the quinolone resistance-determining regions of A and C. Point mutations in C, an efflux pump regulator, were also observed. In this analysis, we chart the molecular evolution of β-lactam resistance in a case of PVE. We show that mutations in regulatory genes controlling efflux and cephalosporinase production contributed to the MDR phenotype.
耐多药(MDR)引起的感染的成功治疗因抗生素耐药性的出现以及人工装置上生物膜的形成而受阻。我们的目的是在一例由MDR引起的人工瓣膜心内膜炎(PVE)的独特病例中,破译耐药性的分子基础。
在7个月期间收集的5株连续的MDR血液分离株,来自一名先前接触过β-内酰胺类抗生素的PVE患者。使用几类抗生素的最低抑菌浓度(MIC)来表明临床耐药特征;使用多位点序列分型和基于重复序列的聚合酶链反应确定分离株的相关性。进行调控基因和耐药基因的扩增和测序。
所有分离株均属于ST298,具有[此处原文似乎缺失相关信息],并且对氟喹诺酮类和碳青霉烯类耐药。在治疗过程中,我们观察到头孢菌素耐药性增加了2倍以上(从4μg/mL增加到>16μg/mL)。AmpC调节因子R的测序显示,头孢菌素耐药分离株中有一个D135N点突变。未鉴定出常见的碳青霉烯酶基因。所有分离株在外膜蛋白OprD的第79位氨基酸处均显示一个提前终止密码子,并且在A和C的喹诺酮耐药决定区有突变。在C(一种外排泵调节因子)中也观察到点突变。
在该分析中,我们描绘了一例PVE中β-内酰胺耐药性的分子演变。我们表明,控制外排和头孢菌素酶产生的调控基因中的突变促成了耐多药表型。